Diatec was formed in 1988 as a distribution company offering products for clinical diagnostic purposes in Norway.
The success of this business led to the development of our own kits and apparatus based on magnetic bead technology and from this subsequently development of our own monoclonal antibodies for our kits.
The success of our own monoclonal antibody production, lead to us producing a range of monoclonal antibodies for sale to the clinical diagnostic market and the life sciences research market.
Our growth in these markets necessitated the need to move to larger premises in Oslo Science Park in 1996.
In 1998 we improved our quality system and achieved ISO 9001 certification. This has later been upgraded to ISO 9001:2008 standard.
Over the years our customer based changed with a greater number of diagnostic producing companies sourcing antibodies from us either from clones provided by them or our clones.
In 2005 we took the decision to divest of our extensive research monoclonal antibody range and concentrate solely on being a monoclonal antibody services business.
The success of the new focus lead in 2010 ,to the commissioning of new facilities with state of the art laboratories and clean rooms in Oslo Science Park. These were we occupied late 2012.
In 2011 we were commissioned to produce our first Active Pharmaceutical Ingredient (A.P.I.) for a new cancer drug, and in 2013 we were commissioned for a second production run for the same A.P.I. for Phase I and II trials